Dallas Formulations Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 24-10-2024
- Paid Up Capital ₹ 3.91 M
as on 24-10-2024
- Company Age 24 Year, 26 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.95 Cr
as on 24-10-2024
- Satisfied Charges ₹ 3.95 Cr
as on 24-10-2024
- Revenue -16.06%
(FY 2023)
- Profit -77.24%
(FY 2023)
- Ebitda -27.34%
(FY 2023)
- Net Worth 0.70%
(FY 2023)
- Total Assets 4.87%
(FY 2023)
About Dallas Formulations
The Corporate was formerly known as Chirayu Ayurveda Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.91 M.
The company currently has active open charges totaling ₹3.95 Cr. The company has closed loans amounting to ₹3.95 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rajesh Gupta and Mukesh Kumar serve as directors at the Company.
- CIN/LLPIN
U24233MP2000PTC014476
- Company No.
014476
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Nov 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Ujjain, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Dallas Formulations?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Gupta  | Director | 16-Jan-2006 | Current |
| Mukesh Kumar | Whole-Time Director | 21-Jul-2022 | Current |
Financial Performance and Corporate Structure Insights of Dallas Formulations.
Dallas Formulations Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 16.06% decrease. The company also saw a substantial fall in profitability, with a 77.24% decrease in profit. The company's net worth moved up by a moderate rise of 0.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dallas Formulations?
In 2023, Dallas Formulations had a promoter holding of 59.21% and a public holding of 40.79%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Dir. Of Industries With Parri Passu Sbi Baddi Creation Date: 17 Aug 2011 | ₹1.29 Cr | Open |
State Bank Of India Creation Date: 11 Nov 2006 | ₹2.66 Cr | Open |
Ing Vysya Bank Limited Creation Date: 28 Nov 2013 | ₹1.75 Cr | Satisfied |
How Many Employees Work at Dallas Formulations?
Dallas Formulations has a workforce of 22 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dallas Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dallas Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
